Antibe Therapeutics
Antibe Therapeutics is a clinical-stage biotechnology company developing therapies for pain and inflammation using its proprietary hydrogen sulfide platform. The company's lead drug, otenaproxesul, aims to provide a safer alternative to opioids and NSAIDs, with significant gastrointestinal safety demonstrated in trials.
Company Overview
Antibe Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for pain and inflammation using its proprietary hydrogen sulfide platform. This platform aims to address common side effects of conventional and nonsteroidal anti-inflammatory drugs (NSAIDs), such as gastrointestinal ulcers and bleeding. The company is targeting areas that include acute and specialized pain as well as inflammatory bowel disease (IBD).
Lead Drug: Otenaproxesul
Antibe Therapeutics' lead drug, otenaproxesul, is designed to serve as a safer alternative to opioids and traditional NSAIDs for treating acute pain. It has shown significant gastrointestinal safety in pre-clinical and clinical trials. The company completed a Phase IIB gastrointestinal safety trial, which demonstrated a substantial reduction in ulceration rates compared to naproxen. Antibe is preparing for a Phase II abdominoplasty trial with enhancements such as a placebo arm, increased sample size, and adaptive design methodology.
Pipeline Drug: ATB-352
Antibe Therapeutics is also working on ATB-352, a drug being developed for a specialized pain indication. This drug is part of the company's broader strategy to offer safer alternatives to existing pain medications, leveraging its hydrogen sulfide platform to minimize common side effects.
Hydrogen Sulfide Platform and Research
The therapeutic potential of Antibe's hydrogen sulfide platform is based on more than 20 years of research. This platform aims to overcome the gastrointestinal complications commonly associated with NSAIDs, such as ulcers and bleeding. By leveraging their extensive research, Antibe aims to produce next-generation therapies that offer enhanced safety profiles and efficacy.
Recent Developments and Financial Position
Antibe Therapeutics ended Q3 2024 with $25 million in cash and equivalents. Despite facing legal challenges, including an unfavorable arbitration decision with Nuance Pharma and a clinical hold by the FDA on otenaproxesul, the company has been recognized for its performance by being named to the 2024 OTCQX Best 50. Antibe has taken measures under the Companies’ Creditors Arrangement Act (CCAA) to manage its financial obligations and continue operations.